Özdemir E.Tosun F.C.Altun G.D.Demir H.Özdemir S.Şen F.2024-06-122024-06-1220202149-6447https://doi.org/10.4274/NTS.GALENOS.2020.0013https://hdl.handle.net/20.500.14551/16801Amyloidosis is a multisystem disease that results from extracellular deposition of amyloid fibriles in tissue and cardiac involvement may be seen. Cardiac amyloidosis is a rare and mostly underdiagnosed cause of heart failure. Several types of amyloid can infiltrate the myocardium. Diagnosis is usually made with endomyocardial biopsy. Scintigraphic imaging with Technetium (Tc-99m) labelled biphosponates may facilitate early detection of cardiac involvement and distinguish various forms of cardiac amyloidosis. The aim of this guideline is to assist nuclear medicine physicians in recommending, imaging, reporting and interpreting the results of scintigraphy with Tc-99m labelled bone radiopharmaceuticals for the evaluation of transthyretin cardiac amyloidosis. © Telif Hakkı 2020 Türkiye Nükleer Tıp Derneği / Nükleer Tıp Seminerleri, Galenos Yayınevi tarafından yayınlanmıştır.tr10.4274/NTS.GALENOS.2020.0013info:eu-repo/semantics/openAccessCardiac Amyloidosis; Scintigraphy; Tc-99m PyrophosphateAmyloid; Bisphosphonic Acid Derivative; Technetium 99m; Article; Attr Amyloidosis; Early Diagnosis; Heart Failure; Heart Muscle Biopsy; Heart Scintiscanning; Human; Practice Guideline; Systemic DiseaseArticle621901972-s2.0-85183311385N/A